"Benefit of implantable cardioverter-defibrillator in patients with imp" by Kanwar Y. Singh, Firas Zahwe et al.
 

Affiliations

Aurora Cardiovascular Services, Department of Electrophysiology, Department of Cardiology, Cardiovascular Data Services, Aurora Health Care, Aurora Research Institute

Presentation Notes

Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Abstract

Conclusions: In the Aurora cohort of patients with "transient" LV dysfunction recovered to EF≥40%, characteristics of ICD recipients were similar to prior primary prevention ICD trials. ICD recipients were more likely to have diabetes, and EF improved to a lesser degree and over a longer period. An associated between presence of ICD and better all-cause survival was observed. This difference was driven by a benefit in patients with EF 40-49%.

Our findings suggest: in patients who develop significant LV dysfunction, recovery of LV function to EF>35% does not afford adequate SCD protection, and that ICD therapy may be appropriate and protective in patients with EF improved up to 49%.

Document Type

Poster


 

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.